ResearchIn-Press PreviewMetabolismNeuroscienceOncology
Open Access |
10.1172/jci.insight.191465
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Kant, S. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Zhao, Y. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Kesarwani, P. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Alka, K. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Oyeniyi, J. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Mohammad, G. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Ashrafi, N. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Graham, S. in: PubMed | Google Scholar
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by
Miller, C.
in:
PubMed
|
Google Scholar
|
1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America
2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America
3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
Find articles by Chinnaiyan, P. in: PubMed | Google Scholar
Published December 9, 2025 - More info
Enhanced lipid metabolism, which involves the active import, storage, and utilization of fatty acids from the tumor microenvironment, plays a contributory role in malignant glioma transformation; thereby, serving as an important gain of function. In this work, through studies initially designed to understand and reconcile possible mechanisms underlying the anti-tumor activity of a high-fat ketogenic diet, we discovered that this phenotype of enhanced lipid metabolism observed in glioblastoma may also serve as a metabolic vulnerability to diet modification. Specifically, exogenous polyunsaturated fatty acids (PUFA) demonstrate the unique ability of short-circuiting lipid homeostasis in glioblastoma cells. This leads to lipolysis-mediated lipid droplet breakdown, an accumulation of intracellular free fatty acids, and lipid peroxidation-mediated cytotoxicity, which was potentiated when combined with radiation therapy. Leveraging this data, we formulated a PUFA-rich modified diet that does not require carbohydrate restriction, which would likely improve long-term adherence when compared to a ketogenic diet. The modified PUFA-rich diet demonstrated both anti-tumor activity and potent synergy when combined with radiation therapy in mouse glioblastoma models. Collectively, this work offers both a mechanistic understanding and a potentially translatable approach of targeting this metabolic phenotype in glioblastoma through diet modification and/or nutritional supplementation that may be readily integrated into clinical practice.